Drug Profile
Vericiguat - Bayer HealthCare Pharmaceuticals/Merck & Co
Alternative Names: BAY 102; BAY-1021189; MK-1242; VERQUVOLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Developer Bayer HealthCare Pharmaceuticals; Merck & Co
- Class Amines; Carbamates; Fluorobenzenes; Heart failure therapies; Pyrazoles; Pyridines; Pyrimidines; Small molecules; Vasodilators
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic heart failure
- Phase II Metabolic syndrome
- No development reported Coronary artery disease
Most Recent Events
- 08 Jan 2024 Bayer plans a phase IIb trial for Chronic heart failure in USA, Argentina, Hungary, Italy, Poland, Spain, Sweden (PO, Tablet) in May 2024 (NCT06195930),
- 16 Jun 2023 Phase-II clinical trials in Metabolic syndrome in USA (PO) (NCT05711719)
- 25 May 2023 Chemical structure information added